surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университет10.34822/2304-9448-2020-2-73-79surgumed-326Research ArticleМЕДИКО-БИОЛОГИЧЕСКИЕ НАУКИ. ОБЗОР ЛИТЕРАТУРЫLIFE SCIENCES. REVIEWSФАКТОРЫ РИСКА И ПАТОГЕНЕЗ РАЗВИТИЯ ДЕГЕНЕРАТИВНОГО АОРТАЛЬНОГО ПОРОКАRISK FACTORS AND PATHOGENESIS OF DEGENERATIVE AORTIC DISEASEShttps://orcid.org/0000-0002-6777-0814ЧугуновВ. В.ChugunovV. V.

аспирант кафедры кардиологии, Медицинский институт, Сургутский государственный университет; врач – сердечно-сосудистый хирург;

Е-mail: ruapostol@gmail.com

Postgraduate, Department of Cardiology, District Cardiology Dispensary

https://orcid.org/0000-0001-9419-1167МолчановА. Н.MolchanovA. N.

кандидат медицинских наук, доцент кафедры кардиологии, Медицинский институт, сердечно-сосудистый хирург

Candidate of Sciences (Medicine), Associate Professor, Department of Cardiology, Medical Institute, Cardio-vascular Surgeon

https://orcid.org/0000-0003-1145-3710НаумоваЛ. А.NaumovaL. A.

доктор медицинских наук, профессор кафедры патофизиологии и общей патологии, Медицинский институт

E-mail: naumovala@yandex.ru

Doctor of Sciences (Medicine), Professor of the Department of Pathophysiology and General Pathology, Medical Institute

Окружной кардиологический диспансер «Центр диагностики и сердечно-сосудистой хирургии», СургутРоссияMedical Institute, Surgut State University,District Cardiology DispensaryRussian FederationСургутский государственный университет, Окружной кардиологический диспансер «Центр диагностики и сердечно-сосудистой хирургии»РоссияSurgut State University, District Cardiology Dispensary “Center for Diagnostics and Cardiovascular Surgery”, SurgutRussian FederationСургутский государственный университет, СургутРоссияSurgut State University, SurgutRussian Federation20200207202002 (44)7379Copyright © Чугунов В.В., Молчанов А.Н., Наумова Л.А., 20202020Чугунов В.В., Молчанов А.Н., Наумова Л.А.Chugunov V.V., Molchanov A.N., Naumova L.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/326

Цель – на основании опубликованных данных проанализировать факторы риска и патогенетические механизмы формирования дегенеративного аортального стеноза, а также возможность рассмотрения их как мишени для проведения консервативной терапии. Материал и методы. В работе использованы базы данных PubMed, Scopus, Cochrane Database of Systematic Reviews и др. с глубиной поиска 15 лет. Ключевые слова для поиска: дегенеративный стеноз аортального клапана, аортальный клапан. Результаты. В современной литературе дегенеративный стеноз аортального клапана рассматривается как многофакторный и многоступенчатый процесс, включающий такие этапы, как повреждение и развитие эндотелиальной дисфункции, накопление липидов, развитие асептического воспаления и дезадаптивной миофибробластической и остеогенной трансформации клапанных интерстициальных клеток, ведущей к фиброзу и кальцификации аортального клапана. При этом накаждом из этапов имеется своя мишень для замедления развития патологического процесса.

The study aims to analyze the published data on pathogenesis for the development of degenerative aorticvalve stenosis as a possible target for conservative therapy. Material and methods. Literary sources from various databases such as PubMed, Scopus, Cochrane Database of Systematic Reviews with a search depth of 15 years are selected. “Degenerative aortic valve stenosis” and “aortic valve” are used as keywords. Results. Degenerative aortic valve stenosis is a multi-stage and multifactorial process. The pathological process includes stages: endothelial dysfunction and damage, lipid accumulation, aseptic inflammation, maladaptive myofibroblastic, and osteogenic transformation of valvular interstitial cells, which ultimately leads to fibrosis and calcification of the aortic valve. Each of the stages has its own target in order to slow down the pathological process.

дегенеративный стеноз аортального клапанааортальный клапан.degenerative aortic valve stenosisaortic valve.ReferencesHull M. C., Morris C. G., Pepine C. J., Mendenhall N. Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodjkin Lymphoma Treated with Radiation Therapy // JAMA 2003. No. 290. Р. 2831–2837.Hull M. C., Morris C. G., Pepine C. J., Mendenhall N. ValvularKon N. D., Westaby S., Amarasena N., Pillai R., Cordell A. R. Comparison оf Implantation Techniques Using Freestyle Stentless Porcine Aortic Valve // The Annals of Thoracic Surgery. 1995. No. 59. P. 857.Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodjkin Lymphoma Treated with Radiation TherapyIung B., Baron G., Butchart E. G. et al. A Prospective Survey of Patients with Valvular Heart Disease in Europe: the Euro Heart Survey on Valvular Heart Disease // European Heart Journal. 2003. No. 24. Р. 1231–1243.// JAMA 2003. No. 290. Р. 2831–2837.Yutzey K. E., Demer L. L., Body S. C. et al. Calcific Aortic Valve Disease: a Consensus Summary from the Alliance of Investigators on Calcific Aortic Valve Disease // Arteriosclerosis, Thrombosis and Vascular Biology. 2014. No. 34. 2387–2393.Kon N. D., Westaby S., Amarasena N., Pillai R., Cordell A. R. ComparisonHutcheson J. D., Aikawa E., Merryman W. D. Potential Drug Targets for Calcific Aortic Valve Disease // Nature Reviews Cardiology. 2014. No. 11. Р. 218–231.оf Implantation Techniques Using Freestyle Stentless Porcine Aortic Valve // The Annals of Thoracic Surgery. 1995. No. 59. P. 857.Gould S. T., Srigunapalan S., Simmons C. A., Anseth K. S.Iung B., Baron G., Butchart E. G. et al. A Prospective Survey of Patients with Valvular Heart Disease in Europe: the Euro Heart Survey on Valvular Heart Disease // European Heart Journal. 2003. No. 24. Р. 1231–1243.Hemodynamic and Cellular Response Feedback in Calcific Aortic Valve Disease // Circulation Research. 2013. No. 113. Р. 186–197.Yutzey K. E., Demer L. L., Body S. C. et al. Calcific Aortic Valve Disease:Wang H., Leinwand L. A., Anseth K. S. Cardiac Valve Cells and their Microenvironment – Insights from In Vitro Studies // Nature Reviews Cardiology. 2014. No. 11. Р. 715–727. DOI 10.1038/ nrcardio.2014.162.a Consensus Summary from the Alliance of Investigators on CalcificCapoulade R., Mahmut A., Tastet L. et al. Impact of Plasma Lp-PLA2Aortic Valve Disease // Arteriosclerosis, Thrombosis and VascularActivity on the Progression of Aortic Stenosis: the PROGRESSA studyBiology. 2014. No. 34. 2387–2393.// JACC Cardiovascular Imaging. 2014. No. 8. Р. 26–33.Hutcheson J. D., Aikawa E., Merryman W. D. Potential Drug TargetsRutkovskiy A., Malashicheva A., Sullivan G. et al. Valve Interstitial Cells: the Key to Understanding the Pathophysiology of Heart Valve Calcification // Journal of the American Heart Association. 2017. No. 6. DOI 10.1161/JAHA.117.006339.for Calcific Aortic Valve Disease // Nature Reviews Cardiology. 2014.Cote N., Pibarot P., Clavel M. A. Incidence, Risk Factors, Clinical Impact, and Management of Bioprosthesis Structural Valve Degeneration // Current Opinion in Cardiology. 2017. No. 32. Р. 123–129. DOI 10.1097/HCO.0000000000000372.No. 11. Р. 218–231.Yip C. Y., Simmons C. A. The Aortic Valve Microenvironment and itsGould S. T., Srigunapalan S., Simmons C. A., Anseth K. S. Hemodynamic and Cellular Response Feedback in Calcific Aortic Valve Disease // Circulation Research. 2013. No. 113. Р. 186–197.Role in Calcific Aortic Valve Disease // Cardiovascular Pathology. 2011. No. 20. Р. 177–182.Wang H., Leinwand L. A., Anseth K. S. Cardiac Valve Cells and their Microenvironment – Insights from In Vitro Studies // Nature Reviews Cardiology. 2014. No. 11. Р. 715–727. DOI 10.1038/ nrcardio.2014.162.Mathieu P., Boulanger M. C., Bouchareb R. Molecular Biology ofCapoulade R., Mahmut A., Tastet L. et al. Impact of Plasma Lp-PLA2Calcific Aortic Valve Disease: Towards New Pharmacological TherapiesActivity on the Progression of Aortic Stenosis: the PROGRESSA study // JACC Cardiovascular Imaging. 2014. No. 8. Р. 26–33.// Expert Review Cardiovascular Therapy. 2014. No. 12. Р. 851–862.Rutkovskiy A., Malashicheva A., Sullivan G. et al. Valve InterstitiCalcification // Journal of the American Heart Association. 2017. No. 6. DOI 10.1161/JAHA.117.006339.Gould S. T., Srigunapalan S., Simmons C. A. et al. Hemodynamic and Cellular Response Feedback in Calcific Aortic Valve Disease // Circulation Research. 2013. No. 113. Р. 186–197. DOI 10.1161/ CIRCRESAHA.112.300154.Cote N., Pibarot P., Clavel M. A. Incidence, Risk Factors, Clinical Impact, and Management of Bioprosthesis Structural Valve Degeneration // Current Opinion in Cardiology. 2017. No. 32. Р. 123–129. DOI 10.1097/HCO.0000000000000372.Dweck M. R., Boon N. A., Newby D. E. Calcific Aortic Stenosis a Disease of the Valve and the Myocardium // Journal of the American College of Cardiology. 2012. No. 60. Р. 1854–1863. DOI 10.1016/j.jacc.2012.02.093.Yip C. Y., Simmons C. A. The Aortic Valve Microenvironment and its Role in Calcific Aortic Valve Disease // Cardiovascular Pathology. 2011. No. 20. Р. 177–182.Michelena H. I., Prakash S. K., Corte A. D. et al. Bicuspid AorticMathieu P., Boulanger M. C., Bouchareb R. Molecular Biology of Calcific Aortic Valve Disease: Towards New Pharmacological Therapies // Expert Review Cardiovascular Therapy. 2014. No. 12. Р. 851–862.Valve: Identifying Knowledge Gaps and Rising to the ChallengeGould S. T., Srigunapalan S., Simmons C. A. et al. Hemodynamic and Cellular Response Feedback in Calcific Aortic Valve Disease // Circulation Research. 2013. No. 113. Р. 186–197. DOI 10.1161/ CIRCRESAHA.112.300154.from the International Bicuspid Aortic Valve Consortium (BAVCon) // Circulation. 2014. No. 129. Р. 2691–2704. DOI 10.1161/ CIRCULATIONAHA.113.007851.Dweck M. R., Boon N. A., Newby D. E. Calcific Aortic Stenosis a DiseaseCoffey S., Cox B., Williams M. J. The Prevalence, Incidence, Progression, and Risks of Aortic Valve Sclerosis: a Systematic Review and Meta-Analysis // Journal of the American College of Cardiology. No. 63 (25). Р. 2852–2861. DOI 10.1016/j.jacc.2014.04. 018.of the Valve and the Myocardium // Journal of the American College of Cardiology. 2012. No. 60. Р. 1854–1863. DOI 10.1016/j.jacc.2012.02.093.Witt W., Jannasch A., Burkhard D. et al. Sphingosine-1-PhosphateMichelena H. I., Prakash S. K., Corte A. D. et al. Bicuspid AorticInduces Contraction of Valvular Interstitial Cells from Porcine Aortic Valves // Cardiovascular Research. 2012. No. 93. Р. 490–497. DOI 10.1093/cvr/cvs002.Valve: Identifying Knowledge Gaps and Rising to the Challenge from the International Bicuspid Aortic Valve Consortium (BAVCon) // Circulation. 2014. No. 129. Р. 2691–2704. DOI 10.1161/ CIRCULATIONAHA.113.007851.Chen J. H., Chen W. L., Sider K. L. et al. β-Catenin Mediates Mechanically Regulated, Transforming Growth Factor-β1-Induced Myofibroblast Differentiation of Aortic Valve Interstitial Cells. Arteriosclerosis // Thrombosis and Vascular Biology. 2011. No. 31. Р. 590–597. DOI 10.1161/ATVBAHA.110.220061.Coffey S., Cox B., Williams M. J. The Prevalence, Incidence Progression, and Risks of Aortic Valve Sclerosis: a Systematic Review and Meta-Analysis // Journal of the American College of Cardiology. No. 63 (25). Р. 2852–2861. DOI 10.1016/j.jacc.2014.04. 018.Wang H., Tibbitt M. W., Langer S. J. et al. Hydrogels Preserve Native Phenotypes of Valvular Fibroblasts through an Elasticity-Regulated PI3K/AKT Pathway // Proceedings of the National Academy of Sciences. No. 110 (48). Р. 19336–19341. DOI 10.1073/pnas. 1306369110.Witt W., Jannasch A., Burkhard D. et al. Sphingosine-1-Phosphate Induces Contraction of Valvular Interstitial Cells from Porcine Aortic Valves // Cardiovascular Research. 2012. No. 93. Р. 490–497. DOI 10.1093/cvr/cvs002.Liu J., Khalil R. A. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders // Progress in Molecular Biology and Translational Science. 2017. Р. 355–420. DOI 10.1016/ bs. pmbts.2017.04.003.Chen J. H., Chen W. L., Sider K. L. et al. β-Catenin Mediates Mechanically Regulated, Transforming Growth Factor-β1-Induced Myofibroblast Differentiation of Aortic Valve Interstitial Cells. Arteriosclerosis // Thrombosis and Vascular Biology. 2011. No. 31. Р. 590–597. DOI 10.1161/ATVBAHA.110.220061.Aikawa E., Aikawa M., Libby P. et al. Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease // Circulation. No. 119 (13). Р. 1785–1794. DOI 10.1161/ CIRCULATIONAHA.108.827972.Wang H., Tibbitt M. W., Langer S. J. et al. Hydrogels Preserve NativePerrotta I., Russo E., Camastra C. et al. New Evidence for a Critical Role of Elastin in Calcification of Native Heart Valves: Immunohistochemical and Ultrastructural Study with Literature Review // Histopathology. No. 59 (3). Р. 504–513. DOI 10.1111/j.1365-2559.2011.03977.x.Phenotypes of Valvular Fibroblasts through an Elasticity-Regulated PI3K/AKT Pathway // Proceedings of the National Academy of Sciences. No. 110 (48). Р. 19336–19341. DOI 10.1073/pnas. 1306369110.Misfeld M., Sievers H. H. Heart Valve Macro- and MicrostructureLiu J., Khalil R. A. Matrix Metalloproteinase Inhibitors as\ Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders // Progress in Molecular Biology and Translational Science. 2017. Р. 355–420. DOI 10.1016/ bs. pmbts.2017.04.003.// Philosophical Transactions of the Royal Society B: Biological Sciences. No. 362 (1484). Р. 1421–1436. DOI 10.1098/rstb.2007.2125.Aikawa E., Aikawa M., Libby P. et al. Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease // Circulation. No. 119 (13). Р. 1785–1794. DOI 10.1161/ CIRCULATIONAHA.108.827972.Perrotta I., Moraca F. M., Sciangula A. et al. HIF-1α and VEGF: Immunohistochemical Profile and Possible Function in Human Aortic Valve Stenosis // Ultrastructural Pathology. No. 39 (3). Р. 198–206. DOI 10.3109/ 01913123.2014.991884.Perrotta I., Russo E., Camastra C. et al. New Evidence for a Critical Role of Elastin in Calcification of Native Heart Valves: Immunohistochemical and Ultrastructural Study with Literature Review // Histopathology. No. 59 (3). Р. 504–513. DOI 10.1111/j.1365- 2559.2011.03977.x.Syvaranta S., Helske S., Laine M., et al. Vascular Endothelial Growth Factor-Secreting Mast Cells and Myofibroblasts: a Novel Self-Perpetuating Angiogenic Pathway in Aortic Valve Stenosis // Arteriosclerosis, Thrombosis and Vascular Biology. No. 30 (6). Р. 1220–1227. DOI 10.1161/ATVBAHA.109.198267.Misfeld M., Sievers H. H. Heart Valve Macro- and Microstructure // Philosophical Transactions of the Royal Society B: BiologicalCote N., Mahmut A., Bosse Y. et al. Inflammation is Associated withSciences. No. 362 (1484). Р. 1421–1436. DOI 10.1098/rstb.2007.2125.the Remodeling of Calcific Aortic Valve Disease // Inflammation. No. 36 (3). Р. 573–581. DOI 10.1007/s10753-012-9579-6.Perrotta I., Moraca F. M., Sciangula A. et al. HIF-1α and VEGF:Dweck M. R., Boon N. A., Newby D. E. Calcific Aortic Stenosis a Disease of the Valve and the Myocardium // Journal of the American College of Cardiology. No. 60 (19). Р. 1854–1863. DOI 10.1016/j. jacc.2012.02.093.Immunohistochemical Profile and Possible Function in Human Aortic Valve Stenosis // Ultrastructural Pathology. No. 39 (3). Р. 198–206. DOI 10.3109/ 01913123.2014.991884.Liu X., Xu Z. Osteogenesis in Calcified Aortic Valve Disease: fromSyvaranta S., Helske S., Laine M., et al. Vascular Endothelial Growth Factor-Secreting Mast Cells and Myofibroblasts: a Novel Self-Perpetuating Angiogenic Pathway in Aortic Valve Stenosis // Arteriosclerosis, Thrombosis and Vascular Biology. No. 30 (6). Р. 1220–1227. DOI 10.1161/ATVBAHA.109.198267.Histopathological Observation Towards Molecular UnderstandingCote N., Mahmut A., Bosse Y. et al. Inflammation is Associated with the Remodeling of Calcific Aortic Valve Disease // Inflammation. No. 36 (3). Р. 573–581. DOI 10.1007/s10753-012-9579-6.// Progress in Biophysics and Molecular Biology. No. 122 (2). Р. 156–Dweck M. R., Boon N. A., Newby D. E. Calcific Aortic Stenosis a Disease of the Valve and the Myocardium // Journal of the American College of Cardiology. No. 60 (19). Р. 1854–1863. DOI 10.1016/j. jacc.2012.02.093.DOI 10.1016/j.pbiomolbio.2016.02.002.Dorman G., Cseh S., Hajdu I. et al. Matrix Metalloproteinase Inhibitors: a Critical Appraisal of Design Principles and Proposed Therapeutic Utility // Drugs. No. 70 (8). Р. 949–964. DOI 10.2165/11318390-000000000-00000.Parisi V., Leosco D., Ferro G. et al. The Lipid Theory in the Pathogenesis of Calcific Aortic Stenosis // Nutrition, Metabolism and Cardiovascular Disease. No. 25 (6). Р. 519–525. DOI 10.1016/j. numecd.2015.02.001.Peltonen T., Ohukainen P., Ruskoaho H. et al. Targeting Vasoactive Peptides for Managing Calcific Aortic Valve Disease // Annals of Internal Medicine. No. 49 (1). Р. 63–74. DOI 10.1080/07853890.2016.1231933.Capoulade R., Chan K. L., Yeang C. et al. Oxidized Phospholipids,Karnik S. S., Unal H., Kemp J. R. et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli // Pharmacological Reviews. No. 67. Р. 754–819. DOI 10.1124/pr.114.010454.Lipoprotein(a), and Progression of Valve Stenosis // Journal of the American College of Cardiology. No. 66 (11). Р. 1236–1246. DOI 10.1016/j.jacc.2015.07.020.Helske S., Lindstedt K. A., Laine M. et al. Induction of Local Angiotensin II Producing Systems in Stenotic Aortic Valves // Journal of the American College of Cardiology. No. 44 (9). Р. 1859–1866. DOI 10.1016/j.jacc.2004.07.054.Mahabadi A. A., Kahlert P., Kahlert H. A. et al. Comparison of Lipoprotein(a)-Levels in Patients ≥ 70 Years of Age with Versus Without Aortic Valve Stenosis (2018) // The American Journal of Cardiology. 2018. No. 122 (4). P. 645–649. DOI 10.1016/j. amjcard.2018.04.046.Bull S., Loudon M., Francis J. M. et al. A Prospective, Double-Blind,Helske S., Otto C. M. Lipid Lowering in Aortic Stenosis: Still SomeRandomized Controlled Trial of the Angiotensin-Converting Enzyme Inhibitor Ramipril in Aortic Stenosis (RIAS trial) // European Heart Journal – Cardiovascular Imaging. No. 16 (8). Р. 834–841. DOI 10.1093/ehjci/jev043.Light at the End of the Tunnel? // Circulation. No. 119 (20). Р. 2653–2655. DOI 10.1161/ CIRCULATIONAHA.109.864421.Nadir M. A., Wei L., Elder D. H. et al. Impact of Renin-AngiotensinOsman L., Yacoub M. H., Latif N. et al. Role of Human Valve Interstitial Cells in Valve Calcification and Their Response to Atorvastatin// Circulation. 2006. No. 114. Sup. 1. P. 547–552. DOI 10.1161/ CIRCULATIONAHA.105.001115.System Blockade Therapy on Outcome in Aortic Stenosis // J Journal of the American College of Cardiology. No. 58 (6). Р. 570–576. DOI 10.1016/j.jacc.2011.01.063.Teo K. K., Corsi D. J., Tam J. W. et al. Lipid Lowering on Progression of Mild to Moderate Aortic Stenosis: Meta-Analysis of the Randomized Placebo-Controlled Clinical Trials on 2344 Patients // Canadian Journal of Cardiology. No. 27 (6). Р. 800–808. DOI 10.1016/j.cjca.2011.03.012.Helske-Suihko S., Laine M., Lommi J. et al. Is Blockade of the Renin-Yeang C., Hung M. Y., Byun Y. S. et al. Effect of Therapeutic Interventions on Oxidized Phospholipids on Apolipoprotein B100 and Lipoprotein(a) // Journal of Clinical Lipidology. No. 10 (3). 594–603. DOI 10.1016/j.jacl.2016.01.005.Angiotensin System Able to Reverse the Structural and FunctionalSteiner I., Stejskal V., Zacek P. Mast Cells in Calcific Aortic StenosisRemodeling of the Left Ventricle in Severe Aortic Stenosis? // Journal of Cardiovascular Pharmacology. No. 65 (3). Р. 233–240. DOI 10.1097/FJC.0000000000000182.// Pathology – Research and Practice. No. 214 (1). Р. 163–168. DOI// Pathology – Research and Practice. No. 214 (1). Р. 163–168. DOI1016/j.prp.2017.07.016.1016/j.prp.2017.07.016.Muller W. A. Mechanisms of Transendothelial Migration ofMuller W. A. Mechanisms of Transendothelial Migration ofLeukocytes // Circulation Research. No. 105 (3). Р. 223–230. DOILeukocytes // Circulation Research. No. 105 (3). Р. 223–230. DOI1161/-CIRCRESAHA.109.200717.1161/-CIRCRESAHA.109.200717.Olsson M., Thyberg J., Nilsson J. Presence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves // Arteriosclerosis, Thrombosis and Vascular Biology. No. 19 (5). Р. 1218–1222.Olsson M., Thyberg J., Nilsson J. Presence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves // Arteriosclerosis, Thrombosis and Vascular Biology. No. 19 (5). Р. 1218–1222.Michaud M., Balardy L., Moulis G. et al. Proinflammatory Cytokines,Michaud M., Balardy L., Moulis G. et al. Proinflammatory Cytokines,Aging, and Age-Related Diseases // Journal of the American MedicalAging, and Age-Related Diseases // Journal of the American MedicalDirectors Association. No. 14 (12). Р. 877–882. DOI 10.1016/j.Directors Association. No. 14 (12). Р. 877–882. DOI 10.1016/j.jamda.2013.05.009.jamda.2013.05.009.Lin C. P., Huang P. H., Lai C. F. et al. Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR−/− Mice Fed with High Fat Diet Via Down-Regulation of Tumor NecrosisLin C. P., Huang P. H., Lai C. F. et al. Simvastatin Attenuates Oxidative Stress, NF-κB Activation, and Artery Calcification in LDLR−/− Mice Fed with High Fat Diet Via Down-Regulation of Tumor NecrosisFactor-α and TNF Receptor 1 // Public Library of Science ONE. No. 10Factor-α and TNF Receptor 1 // Public Library of Science ONE. No. 10(12). e0143686. DOI 10.1371/journal.pone.0143686.(12). e0143686. DOI 10.1371/journal.pone.0143686.Al-Aly Z., Shao J. S., Lai C. F. et al. Aortic MSx2-Wnt CalcificationAl-Aly Z., Shao J. S., Lai C. F. et al. Aortic MSx2-Wnt CalcificationCascade is Regulated by TNF-Alpha-Dependent Signals in DiabeticCascade is Regulated by TNF-Alpha-Dependent Signals in DiabeticLDLR−/−Mice // Arteriosclerosis, Thrombosis and Vascular Biology.LDLR−/−Mice // Arteriosclerosis, Thrombosis and Vascular Biology.No. 27 (12). Р. 2589–2596. DOI 10.1161/ ATVBAHA.107.153668.No. 27 (12). Р. 2589–2596. DOI 10.1161/ ATVBAHA.107.153668.Kastellanos S. S., Toumpoulis I. K., Aggeli C. et al. Time Course of C-Reactive Protein, Tumour Necrosis Factor-Alpha and Monocyte Chemoattractant Protein-1 Following the Surgical Treatment of Patients With Aortic Valve Stenosis // Hellenic Journal Cardiology. No. 48 (1). Р. 5–14.Kastellanos S. S., Toumpoulis I. K., Aggeli C. et al. Time Course of C-Reactive Protein, Tumour Necrosis Factor-Alpha and Monocyte Chemoattractant Protein-1 Following the Surgical Treatment of Patients With Aortic Valve Stenosis // Hellenic Journal Cardiology. No. 48 (1). Р. 5–14.Nadlonek N., Lee J. H., Reece T. B. et al. Interleukin-1 Beta Induces an Inflammatory Phenotype in Human Aortic Valve Interstitial Cells Through Nuclear Factor Kappa Beta // The Annals Thoracic Surgery. No. 96 (1). Р. 155–162. DOI 10. 1016/j.athoracsur.2013.04.013.Nadlonek N., Lee J. H., Reece T. B. et al. Interleukin-1 Beta Induces an Inflammatory Phenotype in Human Aortic Valve Interstitial Cells Through Nuclear Factor Kappa Beta // The Annals Thoracic Surgery. No. 96 (1). Р. 155–162. DOI 10. 1016/j.athoracsur.2013.04.013.Isoda K., Matsuki T., Kondo H. et al. Deficiency of Interleukin-1 Receptor Antagonist Induces Aortic Valve Disease in BALB/c Mice. Arteriosclerosis // Thrombosis and Vascular Biology. No. 30 (4). Р. 708–715. DOI 10.1161/ATVBAHA.-109.201749.Isoda K., Matsuki T., Kondo H. et al. Deficiency of Interleukin-1 Receptor Antagonist Induces Aortic Valve Disease in BALB/c Mice. Arteriosclerosis // Thrombosis and Vascular Biology. No. 30 (4). Р. 708–715. DOI 10.1161/ATVBAHA.-109.201749.Wang W. G., He Y. F., Chen Y. L. et al. Proprotein Convertase Subtilisin/ Kexin Type 9 Levels and Aortic Valve Calcification: A Prospective, Cross Sectional Study // J Int Med Res. No. 44 (4). Р. 865–874. DOI 10.1177/0300060516648030.Wang W. G., He Y. F., Chen Y. L. et al. Proprotein Convertase Subtilisin/ Kexin Type 9 Levels and Aortic Valve Calcification: A Prospective, Cross Sectional Study // J Int Med Res. No. 44 (4). Р. 865–874. DOI 10.1177/0300060516648030.Winer A., Adams S., Mignatti P. Matrix Metalloproteinase InhibitorsWiner A., Adams S., Mignatti P. Matrix Metalloproteinase Inhibitorsin Cancer Therapy: Turning Past Failures Into Future Successes // Molecular Cancer Therapeutics. No. 17 (6). Р. 1147–1155. DOI 10.1158/1535-7163.MCT-17-0646.in Cancer Therapy: Turning Past Failures Into Future Successes // Molecular Cancer Therapeutics. No. 17 (6). Р. 1147–1155. DOI 10.1158/1535-7163.MCT-17-0646.Dorman G., Cseh S., Hajdu I. et al. Matrix Metalloproteinase Inhibitors: a Critical Appraisal of Design Principles and Proposed Therapeutic Utility // Drugs. No. 70 (8). Р. 949–964. DOI 10.2165/11318390-000000000-00000.Dorman G., Cseh S., Hajdu I. et al. Matrix Metalloproteinase Inhibitors: a Critical Appraisal of Design Principles and Proposed Therapeutic Utility // Drugs. No. 70 (8). Р. 949–964. DOI 10.2165/11318390-000000000-00000.Peltonen T., Ohukainen P., Ruskoaho H. et al. Targeting Vasoactive Peptides for Managing Calcific Aortic Valve DiseasePeltonen T., Ohukainen P., Ruskoaho H. et al. Targeting Vasoactive Peptides for Managing Calcific Aortic Valve Disease// Annals of Internal Medicine. No. 49 (1). Р. 63–74. DOI// Annals of Internal Medicine. No. 49 (1). Р. 63–74. DOI1080/07853890.2016.1231933.1080/07853890.2016.1231933.Karnik S. S., Unal H., Kemp J. R. et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli // Pharmacological Reviews. No. 67. Р. 754–819. DOI 10.1124/pr.114.010454.Karnik S. S., Unal H., Kemp J. R. et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli // Pharmacological Reviews. No. 67. Р. 754–819. DOI 10.1124/pr.114.010454.Helske S., Lindstedt K. A., Laine M. et al. Induction of Local Angiotensin II Producing Systems in Stenotic Aortic Valves // Journal of the American College of Cardiology. No. 44 (9). Р. 1859–1866. DOI 10.1016/j.jacc.2004.07.054.Helske S., Lindstedt K. A., Laine M. et al. Induction of Local Angiotensin II Producing Systems in Stenotic Aortic Valves // Journal of the American College of Cardiology. No. 44 (9). Р. 1859–1866. DOI 10.1016/j.jacc.2004.07.054.Bull S., Loudon M., Francis J. M. et al. A Prospective, Double-Blind,Bull S., Loudon M., Francis J. M. et al. A Prospective, Double-Blind,Randomized Controlled Trial of the Angiotensin-Converting Enzyme Inhibitor Ramipril in Aortic Stenosis (RIAS trial) // European Heart Journal – Cardiovascular Imaging. No. 16 (8). Р. 834–841. DOI 10.1093/ehjci/jev043.Randomized Controlled Trial of the Angiotensin-Converting Enzyme Inhibitor Ramipril in Aortic Stenosis (RIAS trial) // European Heart Journal – Cardiovascular Imaging. No. 16 (8). Р. 834–841. DOI 10.1093/ehjci/jev043.Nadir M. A., Wei L., Elder D. H. et al. Impact of Renin-AngiotensinNadir M. A., Wei L., Elder D. H. et al. Impact of Renin-AngiotensinSystem Blockade Therapy on Outcome in Aortic Stenosis // J JournalSystem Blockade Therapy on Outcome in Aortic Stenosis // J Journalof the American College of Cardiology. No. 58 (6). Р. 570–576. DOIof the American College of Cardiology. No. 58 (6). Р. 570–576. DOI1016/j.jacc.2011.01.063.1016/j.jacc.2011.01.063.Helske-Suihko S., Laine M., Lommi J. et al. Is Blockade of the Renin-Angiotensin System Able to Reverse the Structural and Functional Remodeling of the Left Ventricle in Severe Aortic Stenosis? // Journal of Cardiovascular Pharmacology. No. 65 (3). Р. 233–240. DOIHelske-Suihko S., Laine M., Lommi J. et al. Is Blockade of the Renin-Angiotensin System Able to Reverse the Structural and Functional Remodeling of the Left Ventricle in Severe Aortic Stenosis? // Journal of Cardiovascular Pharmacology. No. 65 (3). Р. 233–240. DOI1097/FJC.0000000000000182.1097/FJC.0000000000000182.

The authors declare that there are no conflicts of interest present.